- Y-mAbs Therapeutics Inc's (NASDAQ:YMAB) CEO and Board Member, Claus Moller, has stepped down from his position effective immediately.
- Thomas Gad, the Company's Founder, Chairman & President, has assumed the interim CEO and Board Member role.
- In addition, Mr. Gad has stepped down as Chairman, and Jim Healy, current Board Member and Chair of the Compensation Committee, has been appointed as Chairman of the Board.
- The Company posted preliminary Q1 FY22 Danyelza sales of $10.5 million, with a $45-50 million full-year revenue guidance.
- The omburtamab FDA marketing application was resubmitted in March and is currently under review with the FDA.
- The Company held a cash balance of $156.7 million, which provides a runway to mid-2024.
- For 2022, Y-mAbs expects operating expenses of $162-167 million and a net cash burn of $78-83 million.
- Price Action: YMAB shares closed at $9.35 on Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Y-MAbs Therapeutics' CEO Exits, Expects FY22 Danyelza Sales of Up To $50M
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks